Sasha Watson Highlights ctDNA’s Potential for Early Colon Cancer Detection and Personalized Treatment Strategies

Sasha Watson, PharmD, BCOP, presented insights into the developing role of circulating tumor DNA (ctDNA) in colon cancer management. Her discussion focused on ctDNA’s potential contributions to precision oncology through improved early detection of the disease, better decision-making regarding adjuvant therapy, and more effective monitoring of disease recurrence and the emergence of treatment resistance. Watson explained that ctDNA analysis could offer a new approach to detecting colon cancer earlier. In addition, ctDNA may also provide clinicians with data to individualize adjuvant therapy plans based on a patient’s specific tumor characteristics and treatment response. Finally, monitoring ctDNA levels could allow for the earlier detection of disease recurrence and the identification of mechanisms driving resistance to treatment, she stated.

Newsflash | Powered by GeneOnline AI
Date: April 30, 2025

Related posts:

Only 6.9% of Drug-Resistant Infections Treated Effectively in Study Across Eight Low- and Middle-Income Nations A protein link between brain diseases and leaky blood vessels New Therapies in Clinical Trials Aim to Extend Survival for Transplant-Ineligible Multiple Myeloma Patients Specialty Pharmacies Mandated to Develop Health Equity Programs Addressing Diverse Patient Needs

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後